Harvard Bioscience (HBIO) Set to Announce Earnings on Thursday

Harvard Bioscience (NASDAQ:HBIO) is set to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Harvard Bioscience has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.06). Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. The company had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million.

Harvard Bioscience Price Performance

HBIO stock opened at $2.45 on Thursday. Harvard Bioscience has a one year low of $2.30 and a one year high of $5.56. The company’s fifty day moving average price is $2.65 and its 200-day moving average price is $3.02. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.94 and a current ratio of 2.05. The company has a market capitalization of $106.40 million, a PE ratio of -12.25 and a beta of 1.29.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.